Welcome to our dedicated page for Addus HomeCare SEC filings (Ticker: ADUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Addus HomeCare Corporation filings document a home care provider with personal care, hospice and home health operations. Form 8-K reports furnish quarterly and annual results of operations, Regulation FD disclosures and exhibit press releases, while amended 8-K filings provide acquisition-related financial statements and pro forma information for the completed purchase of Gentiva's personal care business by Addus HealthCare, a wholly owned subsidiary.
Proxy and annual-meeting filings cover board elections, auditor ratification, executive compensation votes and related governance disclosures. The filing record also includes capital-structure, material-event and shareholder-vote disclosures for the company's common stock.
Addus HomeCare Corporation (ADUS) reported the voting results from its 18 June 2025 Annual Meeting of Stockholders in an 8-K filing (Item 5.07).
- Quorum: 17,431,919 shares (94.7% of the 18,399,139 shares outstanding) were represented.
- Director elections: Class I nominees Esteban López, M.D. (93.2% support), Jean Rush (95.2% support) and Susan T. Weaver, M.D. (91.5% support) were elected for terms expiring in 2028. Broker non-votes totaled 875,876 for each nominee.
- Auditor ratification: PricewaterhouseCoopers LLP was re-appointed with 17,369,357 votes for (99.7%), 59,873 against and 2,689 abstentions.
- Say-on-Pay: Executive compensation received 15,216,859 votes for (92.0%), 1,330,522 against and 8,662 abstentions.
- Say-on-Pay frequency: An annual vote was favored by 15,903,154 shares (92.9%), compared with 632,362 for triennial, 3,984 for biennial and 16,543 abstentions. No broker non-votes.
- Board response: The Board will continue to hold the advisory Say-on-Pay vote annually until the next required frequency vote.
The filing contains no financial performance data, strategic transactions or changes to previously reported guidance. All proposals were approved by wide margins, indicating solid shareholder support for governance, compensation and audit practices.
Form 4 filing – Addus HomeCare Corp. (ADUS)
Non-employee director Jean Rush reported the grant of 1,172 shares of restricted common stock on 06/18/2025. The award was received at $0 cost and is scheduled to vest in full on 06/18/2026. Following the transaction, Rush’s direct beneficial ownership stands at 9,221 shares. No derivative securities were created or disposed of, and there were no share sales.
The transaction appears to be a routine component of director equity compensation designed to align board and shareholder interests. The filing, signed by attorney-in-fact Brian Poff on 06/20/2025, does not reference a Rule 10b5-1 trading plan.
Form 4 filing overview – Addus HomeCare Corp. (ADUS)
Director Darin J. Gordon reported the grant of 1,172 restricted common shares on 18-Jun-2025. The award was received at $0 cost under a standard non-employee director compensation plan and will vest in full on 18-Jun-2026. Following the grant, Gordon’s direct ownership rises to 12,795 ADUS shares.
No derivative securities were reported, and there were no sales or open-market purchases. The filing represents routine equity compensation intended to align the director’s interests with shareholders and does not signal a change in company fundamentals.
Addus HomeCare (NASDAQ:ADUS) filed a Form 4 reporting that non-employee director Esteban Lopez received 1,172 restricted shares of common stock on 06/18/2025 at no cost. The grant will vest in full on 06/18/2026. Following the award, Lopez directly owns 4,538 shares of ADUS. No sales, options exercises, or cash transactions were disclosed.
This filing reflects routine board equity compensation and does not signal any change in the company’s financial condition, operations, or strategic direction.
On June 18, 2025, Director Susan T. Weaver reported the acquisition of 1,172 restricted shares of Addus HomeCare Corp. (ADUS) common stock, coded “A” on Form 4, indicating an award or grant from the issuer with no cash consideration ($0 price). The shares will vest in full on June 18, 2026. Following the grant, Weaver’s direct beneficial ownership rises to 12,295 shares. No shares were sold, and no derivative securities were involved. The filing was signed on June 20, 2025 by Attorney-in-Fact Brian Poff.
On June 18, 2025, Addus HomeCare Corp. (ADUS) filed a Form 4 disclosing that non-employee director Mark L. First received 1,172 shares of restricted common stock at no cost. The award is part of routine board compensation and will vest in full on June 18, 2026. After the grant, First’s direct ownership increased to 13,621 shares.
No sales or derivative transactions were reported, and there were no changes to option holdings or other equity instruments. The transaction modestly boosts insider alignment but is not large enough to meaningfully affect the company’s share count or signal a directional view on the stock. Investors typically view such grants as neutral, routine governance events.